The study by Jahnson et al (1995) included 154 patients and showed more complete tumour responses (defined as absence of tumour at cystoscopy with biopsies at 6–7 months) and increased cancer–specific survival among pRB-negative patients, although without reaching statistical significance. This evidence concerns the gene RB1 and cancer.